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Abstract
Aims/Hypothesis: HLA genes, islet autoantibodies and residual C-peptide were studied to determine the independent
association of each exposure with diabetic retinopathy (DR), 15 years after the clinical onset of type 1 diabetes in 15–34 year
old individuals.
Methods: The cohort was identified in 1992 and 1993 by the Diabetes Incidence Study in Sweden (DISS), which investigates
incident cases of diabetes for patients between 15 and 34 years of age. Blood samples at diagnosis were analyzed to
determine HLA genotype, islet autoantibodies and serum C-peptide. In 2009, fundus photographs were obtained from
patient records. Study measures were supplemented with data from the Swedish National Diabetes Registry.
Results: The prevalence of DR was 60.2% (148/246). Autoantibodies against the 65 kD isoform of glutamate decarboxylase
(GADA) at the onset of clinical diabetes increased the risk of DR 15 years later, relative risk 1.12 for each 100 WHO units/ml,
[95% CI 1.02 to 1.23]. This equates to risk estimates of 1.27, [95% CI 1.04 to 1.62] and 1.43, [95% CI 1.06 to 1.94] for
participants in the highest 25
th (GADA.233 WHO units/ml) and 5
th percentile (GADA.319 WHO units/ml) of GADA,
respectively. These were adjusted for duration of diabetes, HbA1c, treated hypertension, sex, age at diagnosis, HLA and C-
peptide. Islet cell autoantibodies, insulinoma-antigen 2 autoantibodies, residual C-peptide and the type 1 diabetes
associated haplotypes DQ2, DQ8 and DQ6 were not associated with DR.
Conclusions: Increased levels of GADA at the onset of type 1 diabetes were associated with DR 15 years later. These results,
if confirmed, could provide additional insights into the pathogenesis of the most common microvascular complication of
diabetes and lead to better risk stratification for both patient screenings and DR treatment trials.
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Introduction
The World Health Organization estimates that more than 180
million people worldwide have diabetes mellitus and this number
is likely to more than double by 2030; about 10% have type 1
diabetes mellitus [1]. Severe visual impairment develops in 10% of
patients and 2% will be blind within 15 years of diagnosis [1].
Blood glucose control has been identified as a critical risk factor in
the development and progression of diabetic retinopathy (DR)
[2,3] but does not completely explain the pathogenesis [4,5]. In
this study we hypothesize that autoimmune processes resulting
from HLA genotype and the relationship of these genes with islet
autoantibody status and residual C-peptide production at the
clinical onset of diabetes are associated with the risk of DR 15
years later.
Type 1 diabetes begins as an autoimmune process that can be
differentiated from type 2 diabetes by the presence of islet
autoantibodies before [6,7,8] and at the time of clinical onset
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17569[9,10]. These include islet cell autoantibodies (ICA) [11,12,13] and
autoantibodies against specific autoantigens including the 65 kD
isoform of glutamic acid decarboxylase (GADA) [14,15,16],
insulinoma-antigen 2 (IA-2A) [17,18,19], insulin (IAA) [20], and
the cation efflux transporter ZnT8 (ZnT8A) [21]. The presence of
these islet autoantibodies is associated with genes in the HLA
complex on chromosome 6, whether they occur alone [22] or with
type 1 diabetes [23,24,25]. The two major risk haplotypes include
DQ2 (DRB1*0301-DQA1*0501-B1*0201) and DQ8 (DRB1*04-
DQA1*0301-B1*0302) and before the age of 15 years, DQ6
(DRB1*1501-DQA1*0102-B1*0602) is a protective haplotype
[26]. Insulin secretion, measured by serum C-peptide, is severely
impaired at the time of diagnosis of type 1 diabetes. There is
typically a continuous decline as the disease progress [27] which is
associated with the number and types of islet autoantibodies
present [28].
The HLA gene complex has been repeatedly studied for its
association with DR for the past 30 years with both negative
[29,30,31,32,33,34,35,36] and positive findings [37,38,39,40,41,
42,43,44,45,46,47,48,49]. Two separate properties of the HLA
complex make it difficult to study. It is polygenic as it contains
several different MHC class I and MHC class II genes and it is the
most polymorphic human gene known with hundreds of variants
for some of these genes [50]. These properties make it difficult to
interpret the results of these studies as they are hindered by small
samples sizes in numerous comparison groups or have little
information about other known risk factors for DR such as blood
glucose control and hypertension. Unlike HLA, there have been
few studies of islet autoantibodies or C-peptide and DR. Two
small cross-sectional studies have reported an inverse relationship
between levels of GADA and the severity of DR suggesting that
GADA may inhibit one or more mediators of DR [51,52]. In the
Diabetes Control and Complications Trial, any C-peptide
secretion, but especially higher and sustained levels of stimulated
C-peptide, was associated with reduced incidences of DR [53].
Previous studies have examined the cross-sectional associations
of HLA, islet autoantibodies and residual C-peptide with DR;
however, none of these studies has accounted for the relationships
between these immunologic markers (Figure 1) to determine the
independent association of each exposure with DR. This incident
inception population-based cohort study uniquely uses measures of
islet autoantibodies and C-peptide determined at the clinical onset
of diabetes while limiting the testing of associations between HLA
and DR to the three haplotypes (DQ2, DQ8 and DQ6) most
closely related to type 1 diabetes.
Methods
Study Population
Written consent was obtained from all participants. The
regional Ethics Board of Lund University, Lund, Sweden,
approved the study.
The cohort for the present study was identified by the Diabetes
Incidence Study in Sweden (DISS) during 1992 and 1993 [54].
DISS is an on-going prospective study that attempts to enroll all
incident cases of diabetes for patients between the ages of 15 and
34 years. Ascertainment in the DISS study has been previously
estimated at 86% for type 1 diabetes and 53% for type 2 diabetes
[55]. Starting in 1992, participants provided blood samples at
diagnosis and each year thereafter for 6 years to determine their
levels of serum C-peptide and islet autoantibodies including ICA,
GADA, IA-2A and IAA. ZnT8A were not described until 2007
[21] and were not analyzed.
A control group [56] of subjects without diabetes were matched
by age and sex as cases were identified by DISS. There were
slightly more controls than cases as some cases were later excluded
when it was determined they did not have diabetes or had
gestational diabetes. The control group provided a reference to
determine the distribution of autoantibody and C-peptide levels in
healthy non-diabetic subjects. This study preceded the Diabetes
Autoantibody Standardization Program and World Health
Organization’s (WHO) standardization of diabetes autoantibodies
so these controls provided the means to determine cut-offs for
autoantibody positive status. Levels of autoantibodies in the
present study have been converted to WHO International units
(GADA, IA-2A) or Juvenile Diabetes Foundation Units (ICA). The
control group was not used in analyses for the present study.
In 2008, we contacted 648 individuals to ask them to participate
in this study (Figure 2). Current addresses were obtained from the
Swedish Population and Address Register. The initial mailing
included a questionnaire and a kit to collect a dried capillary blood
spot. Individuals were contacted twice by mail and those who did
not respond to either mailing received a phone call inviting them
to participate in the study. The participation rate was 60% (392/
648), of these, 74% (289/392) were classified with type 1 diabetes.
HLA Genotyping
HLA genotyping for DRB1, DQA1 and DQB1 was carried out by
PCR amplification of the second exon of the IDDM1 genes followed
by dot blot hybridizations of sequence specific oligo probes and by
restriction fragment length polymorphism using DR- and DQ-based
probes to establish haplotypes [24]. In addition, allele specific PCR
amplification of DRB1 alleles was also used [57,58]. The haplotypes
were classified as DQ2 (DRB1*0301-DQA1*0501-B1*0201), DQ8
(DRB1*04-DQA1*0301-B1*0302), DQ6 (DRB1*1501-DQA1*0102-
B1*0602), or ‘other’, where other is not DQ2, DQ8, or DQ6.
Islet Autoantibodies
The determination of autoantibody levels along with the
sensitivity and specificity of our assays have been previously
described [28]. Briefly, positive values for GADA and IA-2A, were
determined using a cutoff of .97K percentile of the values
defined by a matched control group of 829 individuals [56].
GADA and IA-2A levels were measured by radioimmunoassay
[59,60] and expressed as an index [cpm of tested sample - average
cpm of two negative standards] divided by [cpm of positive
standard - average cpm of two negative standards]. IAA levels
Figure 1. Study design showing the relationship between
human leukocyte antigen genes, islet autoantibodies, C-
peptide and diabetic retinopathy.
doi:10.1371/journal.pone.0017569.g001
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measures the percentage of displacement of the binding of
radioactive insulin. A participant was considered to have type 1
diabetes if the displacement was .0.7% based on previous results
from healthy individuals [61]. ICA levels were determined by
standard immunofluorescence methods as previously described
[62,63]. Participants were considered to have type 1 diabetes if
they tested positive for any of the four autoantibodies at the
baseline exam; GADA.21.2 WHO units/ml, IA-2A.5.88 WHO
units/ml, IAA.0.7% and ICA.6 Juvenile Diabetes Foundation
Units. In the first Diabetes Autoantibody Standardization
Program, sera from selected individuals were used to compare
assay results from participating labs. This GADA assay had 80%
sensitivity and 96% specificity, and the IA-2A assay had 58%
sensitivity and 100% specificity [64]. The sensitivity of the ICA
assay used in this study was 100% and specificity 88% for the
pancreas when tested in the International Diabetes Workshop for
standardization [65]. For this study, we considered the first
blood draw after diagnosis to represent a baseline measure with
the exception of IAA which needed to be completed within 1
month.
C-peptide
C-peptide levels were determined at the Department of Clinical
Chemistry, Ska ˚ne University Hospital SUS, Lund, Sweden using
the EURIA-C-PEPTIDE kit MD315 (EuroDiagnostica, Medeon,
Malmo ¨, Sweden). By this method, the lower detection limit for C-
peptide is 0.13 nmol/l. The 2.5
th percentile of C-peptide for the
matched control group was 0.24 nmol/l [56].
Questionnaire
The study questionnaire asked participants for the name of the
clinic they visited during their most recent eye exam. The health
history portion included the following questions: 1) Have you ever
been told you have hypertension (HTN), impaired kidney function
or increased cholesterol or triacylglycerol by a doctor or nurse? 2)
Have you ever been prescribed medication to control HTN or
cholesterol? 3) Are you currently using medication to control HTN
or cholesterol? 4) Have you smoked more than 100 cigarettes since
becoming diabetic?
HbA1c
Each individual was asked to provide a dried capillary blood
spot which was collected using Roche Kit 14040. Blood glucose
control was estimated by the analysis of the dried blood spot to
determine each participant’s current HbA1c and was conducted by
the Department of Clinical Chemistry, Ska ˚ne University Hospital
SUS, Malmo ¨, Sweden. There is excellent agreement (r=0.99)
between HbA1c values from capillary blood on filter paper and
HbA1c values from venous blood [66].
Retinal Photographs
A copy of the most recent fundus photographs were obtained
from existing patient records. Records were collected from 79
Figure 2. Flow diagram of study participants.
doi:10.1371/journal.pone.0017569.g002
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experienced ophthalmologist [EA], blinded to baseline exposure
status, using the International Clinical Diabetic Retinopathy
Disease Severity Scale [67]. Retinopathy was defined as the
presence of any of the following lesions: microaneurysms, retinal
hemorrhages, hard or soft exudates or intra-retinal microvascular
abnormalities. The primary outcome was the presence of any
retinopathy based on fundus photos. If an individual had DR
graded as questionable or photos were missing, DR classification
from the NDR was used. In general, all the photos were 50u fields,
taken through dilated pupils and stored as a digital image. Photos
for 6 participants were slides, another 6 had either 45u or 60u fields
and only 1 individual did not have their eyes dilated. In cases
where multiple sets of photos were collected the most recent
photos were graded and when both color and red-free photo-
graphs were available only the red-free photographs were used.
Red-free photographs were available for 82% (193/235) of
participants. Less than 7% (15/235) of individuals had photos
with only 1 field centered on the fovea. When 2 fields were
available, 1 was centered on the fovea and the other was either
centered on the optic nerve or nasal to the optic nerve.
National Diabetes Register
Supplemental information on retinopathy, HbA1c and treat-
ment for hypertension was provided by the National Diabetes
Register (NDR). The NDR was implemented in 1996 by the
Swedish Society for Diabetology as a response to the St. Vincent
Declaration for Quality Assurance in Diabetes Care to survey the
treatment and risk factor control in diabetic patients in everyday
clinical practice [68]. Reporting to the NDR is based on
information collected at least once a year during patient visits at
hospital outpatient clinics and primary health centers all over
Sweden. Data is supplied by trained nurses or physicians over the
internet or by a preprinted form. Participation in this register is
voluntary for the clinics and healthcare centers and all patients
must be informed of the register and agree to participate. HbA1c
analyses are quality assured in Sweden. Both clinics and primary
care centers use methods regularly calibrated with the HPLC
Mono-S method.
The percent agreement and kappa of the measures of
medication use for hypertension determined from the study
questionnaire and the data supplied by the NDR was 86.5% and
0.65 respectively. The percent agreement and kappa for the
outcome of the presence of DR in the study photos and the report
supplied in the NDR was 78.0% and 0.55 for all the data and
86.5% and 0.72 for photos taken within 1 year of each other. The
correlation between HbA1c measures collected on filter paper and
those reported in the NDR was 0.80.
Statistical Analysis
Participants with type 2 diabetes were excluded from analyses.
Baseline characteristics were reported for the individuals with type
1 diabetes and a reference group of non-diabetic controls
including the percentage of males and participants initially treated
with insulin; the mean and standard deviation of BMI and age at
clinical diagnosis; and the median and inter-quartile range of C-
peptide and diabetes autoantibody titers. Characteristics of
individuals 15 years after the clinical onset of type 1 diabetes
were also reported including the percentage of participants with
dyslipidemia, kidney disease, treated HTN and who smoked more
than 100 cigarettes since the clinical onset of diabetes. It also
included the mean and standard deviation of glycosylated
hemoglobin.
In the presence of a common outcome, such as DR in our study,
point estimates for exposures associated with an increased risk of
disease will be inflated using logistic regression. To eliminate this
concern, we chose relative risk regression for our analyses. The
Huber-White sandwich estimator of variance [69,70] was
specified.
Our primary analyses was restricted to four models fit to
determine the independent associations of HLA, islet autoanti-
bodies and C-peptide with DR. Model A was used to examine the
crude association between HLA and DR unadjusted for other
covariates except duration of diabetes. Any positive findings here
would not indicate if the association between HLA and DR was
independent or due to HLA’s relationship with islet autoantibodies
and C-peptide, Figure 1. Model B was used to examine the
association between HLA and DR adjusting for precision variables
and potential confounders [HbA1c (%), age at diagnosis (years), sex
and current use of hypertension medication (yes/no)]. In Model C,
islet autoantibodies were added to Model B. This allowed the
determination of the association between islet autoantibodies
whether or not their effects were mediated through C-peptide.
The fully adjusted Model D included HLA (DQ2, DQ8, DQ2/8
and DQ6), islet autoantibodies (GADA, ICA and IA-2A), C-
peptide (nmol/l), age at diagnosis (years), sex, HbA1c (%),
treatment for hypertension (yes/no) and duration of diabetes
(years). This model was used to determine the association of HLA
with DR independent of islet autoantibodies and residual C-
peptide. In addition it established the association of islet
autoantibodies independent of residual C-peptide and adjusted
for the potential confounding by HLA. Lastly this model showed
the association of C-peptide with DR adjusted for confounding by
HLA and islet autoantibodies.
Our secondary analyses examined the risk of retinopathy for
subjects by the rate of change per year in GADA and C-peptide
adjusting for baseline levels. By necessity these analysis were
restricted to subjects with multiple measures. Since a number of
subjects did not have multiple measures, this reduced the sample
size and made comparisons of the risk of retinopathy between the
primary analyses and the secondary analyses difficult. Therefore in
the results from our secondary analysis, we included the findings
from model D restricted to this smaller cohort. In Model E we
looked at the risk of diabetic retinopathy using the last measure of
GADA. In Model F we included the rate of change/year in
GADA & C-peptide adjusting for initial levels. We have previously
reported that GADA levels in GADA positive subjects remained
unchanged after baseline [71] and very few participants with type
1 diabetes had measurable C-peptide by year 4 [28]. Due to the
large confidence intervals for these estimates, particularly the
change in C-peptide, we re-parameterized the model using tertiles
of change in GADA/year and C-peptide/year. The reference
group for the change in GADA/year was the group of subjects
with the fastest decline in GADA/year and the reference group for
C-peptide was the group with the slowest decline in C-peptide/
year. Analyses were performed using Stata 8 (StataCorp. 2003.
Stata Statistical Software: Release 8, StataCorp LP, College
Station, TX).
Results
We had complete data on 85% (246/289) of the participants
with type 1 diabetes (Figure 2). Males comprised 55% (136/246) of
the analytical group, compared to 67% males (219/329) in non-
participants with type 1 diabetes (329/575) from the original
cohort, p,0.01. GADA levels were 18 WHO units/ml higher in
participants than non-participants, p=0.05 but only 15 WHO
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Participants and non-participants did not vary by C-peptide, IA-
2A, ICA, BMI or age at diagnosis and had similar percentages of
individuals who were HLA DQ2, 6 and 8; results not shown.
Most individuals had blood draws within the first month of
diagnosis (89%). Median C-peptide levels were 0.27 nmol/l
(Table 1) which was near the 2.5
th percentile of 829 age matched
non-diabetic controls (0.24 nmol/l). Baseline characteristics of
participants at the clinical onset of type 1 diabetes mellitus by HLA
genotype are presented in Table 1 and by islet autoantibody status
in Table 2. About 2/3
rd of participants with type 1 diabetes were
DQ2, DQ8 or DQ2/8 while 4.9% (12/246) were DQ6. Mean
Table 1. Characteristics of participants at the clinical onset of type 1 diabetes mellitus
a and reference panel of matched controls
b
by HLA genotype.
All
Participants DQ6 DQ8 DQ2 DQ2/8 Other HLA Controls
Number n (%) 246 12 (4.9) 62 (25.2) 39 (15.9) 59 (24.0) 74 (30.0) 837
Males % 55.3 66.7 53.2 38.5 62.7 58.1 55.6
Age (years) Mean (SD) 24.9 (5.4) 27.2 (5.4) 25.6 (5.1) 25.5 (5.4) 22.7 (5.2) 25.2 (5.3) 24.9 (5.9)
GADA (WHO units/ml) Median (IQR) 99 (32–213) 57 (22–262) 95 (28–194) 178 (58–252) 77 (27–170) 90 (44–239) 0 (0 - 0)
ICA (JDF-U) Median (IQR) 54 (0–204) 108 (0–419) 84 (15–204) 54 (0–204) 54 (15–316) 54 (0–204) 0 (0 - 0)
IA-2A(WHO units/ml) Median (IQR) 18 (0–262) 1 (23–214) 200 (0–293) 0 (23–9) 38 (0–235) 16 (0–266) 0 (0 - 0)
C-peptide (nmol/l) Median (IQR) 0.27 (0.18–0.38) 0.29 (0.13–0.55) 0.27 (0.19–0.37) 0.26 (0.16–0.34) 0.29 (0.18–0.48) 0.28 (0.18–0.38) 0.59 (0.44–0.82)
BMI (kg/m
2) Mean (SD) 22.1 (3.7) 22.4 (3.7) 22.0 (3.4) 22.4 (4.4) 21.9 (3.2) 22.1 (3.9) missing
Insulin Medication % 88.9 75.0 87.1 89.7 94.7 87.8 0
Non-Diabetic reference n (%) 837 234 (28.0) 141 (16.8) 141 (16.8) 24 (2.9) 297 (35.5)
aPositive for GADA, ICA, IA-2A (first blood draw after diagnosis) or IAA (during the 1st month after diagnosis).
bThese participants are a reference group of non-diabetics and were not used for analyses in the present study.
DQ6: DRB1*1501-DQA1*0102-B1*0602.
DQ8: DRB1*04-DQA1*0301-B1*0302.
DQ2: DRB1*0301-DQA1*0501-B1*0201.
HLA: human leukocyte antigen.
SD: standard deviation.
GADA: glutamic acid decarboxylase autoantibodies.
WHO: World Health Organization.
IQR: Inter-quartile range.
ICA: islet cell autoantibodies.
JDF-U: Juvenile Diabetes Foundation Units.
IA-2A: insulinoma antigen-2 autoantibodies.
BMI: body mass index.
doi:10.1371/journal.pone.0017569.t001
Table 2. Characteristics of participants at the clinical onset of type 1 diabetes mellitus
a by islet autoantibody status.
GADA+
b ICA+
c IA-2A+
d
Number n 203 177 141
Males % 53.7 56.5 58.2
Age (years) Mean (SD) 25.1 (5.3) 24.7 (5.5) 24.0 (5.3)
GADA (WHO units/ml) Median (IQR) 130 (64–233) 122 (43–233) 98 (27–212)
ICA (JDF-U) Median (IQR) 84 (0–204) 131 (54–316) 131 (35–316)
IA-2A(WHO units/ml) Median (IQR) 12 (0–262) 144 (0–281) 247 (84–300)
C-peptide (nmol/l) Median (IQR) 0.26 (0.18–0.36) 0.27 (0.18–0.37) 0.28 (0.17–0.42)
BMI (kg/m
2) Mean (SD) 21.9 (3.6) 22.2 (3.7) 21.9 (3.4)
Insulin Meds % 91.0 89.7 92.1
aPositive for GADA, ICA, IA-2A (first blood draw after diagnosis) or IAA (during the 1
st month after diagnosis).
bglutamic acid decarboxylase autoantibody (GADA) positive .21.2 WHO units/ml.
cislet cell autoantibody (ICA) positive .6 Juvenile Diabetes Foundation Units.
dinsulinoma antigen 2 autoantibody (IA-2A) positive .5.88 WHO units/ml.
SD: standard deviation.
WHO: World Health Organization.
IQR: Inter-quartile Range.
JDF-U: Juvenile Diabetes Foundation Units.
BMI: body mass index.
doi:10.1371/journal.pone.0017569.t002
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participants 15 years after the clinical onset of type 1 diabetes
mellitus by HLA genotype are presented in Table 3 and by islet
autoantibody status in Table 4. At that time, 15% reported they
take medication for hypertension, 36% had dyslipidemia and 31%
had been cigarette smokers at some time since developing type 1
diabetes. The median duration of diabetes was 15.2 years
(Interquartile Range (IQR) 14.3–15.8).
The distribution of DR in graded photos was bimodal (Table 5).
Based on the photos collected, 31.5% (74/235) of participants had
no DR, however, 11 participants did not have photos and 24 were
graded as questionable. After incorporating NDR data to classify
these 35 individuals, the prevalence of any DR was 60.2% (148/
246).
Relative risk regression models were used to determine the risk
of retinopathy. The point estimate and 95% confidence intervals
did not vary much between the four regression models (Table 6).
In the fully adjusted Model D, increasing levels of GADA were
associated with an increased risk of DR independent of HLA, C-
peptide and known risk factors for DR including HbA1c and
hypertension, RR 1.12 per 100 WHO units/ml, [95% CI 1.02–
1.23]. This yielded risk estimates of 1.27, [95% CI 1.04 to 1.62]
and 1.43, [95% CI 1.06 to 1.94] for participants in the highest 25
th
(GADA.233 WHO units/ml) and 5
th percentile (GADA.319
WHO units/ml) of GADA, respectively. In a similar model,
classifying individuals as GADA positive (GADA.21.2 WHO
units/ml) or negative, the risk for GADA positive participants at
baseline was 1.37 [95% CI 0.98 to 1.92] compared to GADA
negative individuals and using a slightly more strict definition for
GADA positive (GADA.30.0 WHO unit/ml) the relative risk was
1.49 (1.10 to 2.01).
The HLA haplotypes, DQ2, RR 0.76, [95% CI 0.54–1.07],
DQ8, RR 1.06, [95% CI 0.84–1.34], DQ2/8, RR 0.92, [95% CI
0.70–1.19] and DQ6, RR 0.71, [95% CI 0.38–1.34], were not
associated with the presence of any DR compared to participants
who were not HLA DQ2, 8, 2/8 or DQ6. Likewise C-peptide, RR
0.95, [95% CI 0.67–1.33], ICA, RR 1.01, [95% CI 0.98–1.04]
and IA-2A, RR 0.94, [95% CI 0.87–1.01] at the clinical onset of
diabetes were not associated with DR.
In our secondary analyses, the risk of diabetic retinopathy was
1.12 (1.00–1.24) based on the last measure of GADA, slightly less
than risk based on the first measure of GADA 1.15 (1.04–1.28) in
the smaller sample size, Table 7. However, neither the rate of
Table 3. Characteristics of participants 15 years after the clinical onset of type 1 diabetes mellitus
a by HLA genotype.
All Participants DQ6 DQ8 DQ2 DQ2/8 Other HLA
Number n 246 12 62 39 59 74
HbA1c (%) Mean (SD) 7.0 (1.2) 6.6 (0.9) 7.0 (1.1) 7.2 (1.0) 6.9 (1.1) 7.1 (1.5)
HTN Meds
b % 15.0 8.3 21.0 18.0 10.2 13.5
Kidney Disease
b % 14.5 8.3 21.3 18.4 10.2 13.5
Dyslipidemia
b % 36.0 41.7 40.0 21.6 37.9 37.5
Smoker
c % 31.1 8.3 41.7 38.5 27.6 25.0
aPositive for GADA, ICA, IA-2A (first blood draw after diagnosis) or IAA (during the 1st month after diagnosis).
bSelf-report, if missing NDR report.
cSmoked more than 100 cigarettes since the onset of diabetes.
HLA: human leukocyte antigen.
DQ6: DRB1*1501-DQA1*0102-B1*0602.
DQ8: DRB1*04-DQA1*0301-B1*0302.
DQ2: DRB1*0301-DQA1*0501-B1*0201.
SD: standard deviation.
HTN: hypertension.
doi:10.1371/journal.pone.0017569.t003
Table 4. Characteristics of participants 15 years after the
clinical onset of type 1 diabetes mellitus
a by islet
autoantibody status.
GADA+
b ICA+
c IA-2A+
d
Number n 203 177 141
HbA1c (%) Mean (SD) 7.0 (1.2) 7.0 (1.1) 6.9 (1.1)
HTN Meds
e % 16.3 17.5 13.5
Kidney Disease
e % 14.1 15.4 13.6
Dyslipidemia
e % 34.7 35.3 33.3
Smoker
f % 32.8 28.2 31.1
aPositive for GADA, ICA, IA-2A (first blood draw after diagnosis) or IAA (during
the 1st month after diagnosis).
bglutamic acid decarboxylase autoantibody positive .21.2 WHO units/ml.
cislet cell autoantibody positive .6 Juvenile Diabetes Foundation Units.
dinsulinoma antigen 2 autoantibody positive .5.88 WHO units/ml.
eSelf-report, if missing NDR report.
fSmoked more than 100 cigarettes since the onset of diabetes.
doi:10.1371/journal.pone.0017569.t004
Table 5. Grade of retinopathy by eye from 235 participants
with fundus photos.
Right Eye Left Eye Both Eyes
Grade n % n % n %
None 91 38.9 92 39.2 74 31.5
Mild 27 11.5 24 10.2 24 10.2
Moderate 92 39.3 87 37.0 107 45.5
Severe 3 1.3 2 0.9 4 1.7
PDR 2 0.9 2 0.9 2 0.9
Questionable 17 7.3 25 10.6 24 10.2
Unable to grade 2 0.9 3 1.3 0 0.0
Missing 11 11 11
doi:10.1371/journal.pone.0017569.t005
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(RR=1.89, 0.20–17.6) was associated with the risk of diabetic
retinopathy after adjusting for initial GADA and C-peptide level
and the other covariates found in model D. Due to the large
confidence intervals for the estimate of the risk of retinopathy for
change in GADA/year and particularly the change in C-peptide,
we re-parameterized the model using tertiles of change in GADA/
year and C-peptide/year. The reference group for the change in
GADA/year was the group of subjects with the fastest decline in
GADA/year and the reference group for C-peptide was the group
with the slowest decline in C-peptide/year. Rate of loss of GADA
and C-peptide over the first six years after the clinical onset of
diabetes was not associated with the risk of diabetic retinopathy 15
years later, Model F, Table 7.
Discussion
This is the first study to report that increasing levels of GADA
measured at the clinical onset of type 1 diabetes is associated
with increased risk of DR after 15 years of follow-up. This
association was independent of C-peptide, other islet autoanti-
bodies, HLA DQ6, DQ2 and DQ8 as well as other major risk
factors for DR including HbA1c and hypertension. It is also of
interest to note that even though GADA levels tend to be higher
i ns u b j e c t sw h oa r eD Q 2( T a b l e1 ) ,t h eH L Ah a p l o t y p eD Q 2
was not associated with diabetic retinopathy. This implies that
t h ea u t o i m m u n er e s p o n s ei sm o r ei m p o r t a n ti nt h er i s ko f
diabetic retinopathy than the immunogenetic association. In our
secondary analyses, no associations were found between the
change/year in GADA or C-peptide and the risk of diabetic
retinopathy. The risk of retinopathy based on the last measure
of GADA was 1.12 (1.00–1.24) was slightly attenuated
compared to the risk based on the first measure of GADA
1.15 (1.04–1.28).
There are several strengths of this study. Our prospective study
is composed of an incident inception population-based cohort and
had a larger sample size than almost all other similar studies. We
have much better measures of duration of diabetes than studies
that rely on self-report. Our type 1 diabetes population is defined
from laboratory measures of islet autoantibodies instead of
physician classification. In addition, we have measures of islet
autoantibodies and C-peptide at the clinical onset of diabetes
which are not typically available in cross-sectional studies of DR.
One limitation of our study is that we only have a current
HbA1c which may not adequately reflect blood glucose control
over the course of the study. Another possible limitation of our
study is that the cohort consisted of participants who were between
the ages of 15 and 35 at the time of clinical diagnosis of diabetes.
Nevertheless, the cumulative prevalence of any DR in our cohort
was about 60% after 15 years. This is similar to the prevalence of
DR in other studies in Finland, Sweden and Wisconsin where the
range of prevalence at 8 to 10 years duration of type 1 diabetes
varied between 32 and 59% [72]. We had 2 participants (1%) with
proliferative diabetic retinopathy; however, this estimate is likely
too low. In a separate unpublished analysis of all patients receiving
care at the Department of Ophthalmology in Malmo ¨, Sweden, 8%
(4/52) had PDR. This was among all patients with onset of
diabetes ,30 years of age and current duration of diabetes
between 13 and 16 years. In addition, a previous study of a similar
Swedish cohort [73] found that participants with worse DR were
less likely to participate. This combined with our own unpublished
analysis done in Malmo ¨ suggest participants with the worst
retinopathy were less likely to participate in our study.
Table 6. Results of relative risk regression analyses for diabetic retinopathy, primary analysis.
Model A Model B Model C Model D
n=246 RR 95% CI RR 95% CI RR 95% CI RR 95% CI
DQ2/8 (vs. other
a) 0.88 0.67–1.15 0.91 0.70–1.20 0.91 0.70–1.19 0.92 0.70–1.19
DQ6 (vs. other
a) 0.66 0.34–1.30 0.73 0.39–1.39 0.71 0.38–1.34 0.71 0.38–1.34
DQ8 (vs. other
a) 1.03 0.81–1.31 1.03 0.81–1.30 1.07 0.85–1.34 1.06 0.84–1.34
DQ2 (vs. other
a) 0.85 0.61–1.18 0.86 0.62–1.19 0.76 0.54–1.07 0.76 0.54–1.07
GADA (100 WHO units/ml) 1.12 1.02–1.23 1.12 1.02–1.23
log(ICA+0.1) (JDF-U) 1.01 0.98–1.04 1.01 0.98–1.04
IA-2A (100 WHO units/ml) 0.94 0.87–1.01 0.94 0.87–1.01
C-peptide (nmol/l) 0.95 0.67–1.33
HbA1c (%) 1.16 1.07–1.25 1.16 1.07–1.26 1.16 1.07–1.26
HTN meds (yes vs. no) 1.38 1.12–1.70 1.36 1.11–1.67 1.37 1.11–1.68
Age at Diagnosis (years) 1.00 0.98–1.37 0.99 0.98–1.01 0.99 0.98–1.01
Males (vs. Females) 1.12 0.92–1.37 1.16 0.95–1.41 1.16 0.95–1.41
Duration (years) 1.13 1.02–1.26 1.11 1.01–1.22 1.11 1.02–1.22 1.11 1.02–1.22
aOther refers to anyone without DQ2, DQ8 or DQ6.
RR: relative risk.
DQ6: DRB1*1501-DQA1*0102-B1*0602.
DQ8: DRB1*04-DQA1*0301-B1*0302.
DQ2: DRB1*0301-DQA1*0501-B1*0201.
GADA: glutamic acid decarboxylase autoantibodies.
WHO: World Health Organization.
JDF-U: Juvenile Diabetes Foundation Units.
ICA: islet cell autoantibodies.
IA-2A: insulinoma antigen 2 autoantibodies.
doi:10.1371/journal.pone.0017569.t006
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with mechanisms leading to microvascular diseases. Of all the islet
autoantibodies it seems more likely GADA may have some effect
on the development of diabetic retinopathy since GAD65 is
expressed in the neural retina as well as the pancreas and the
central nervous system [14,15,16,74]. GADA levels have been
shown to remain elevated for many years after the clinical onset of
diabetes [71,75]. Among the islet autoantibodies only GADA have
been linked to other clinical disease. For example, GADA has
been implicated in differences in peripheral nerve function,
independent of GADA related differences in glycemic control
[76]. GADA is also a marker for Stiff-Person Syndrome [77] and
bipolar disorder [78]. However, cause and effect relationships for
these associations have not been demonstrated.
Two small cross-sectional studies have examined the relation-
ship between GADA and DR. In one study (n=80) [52],
participants with less severe retinopathy were more likely to be
GADA positive; 50%, 31% & 18% for non-DR, pre-PDR and
PDR respectively. In another study (n=55) GADA levels were
lower in participants with severe disease compared to those
without [51]. The observed inverse relationship between levels of
GADA and the severity of DR in these two studies suggested that
GADA may inhibit one or more mediators of DR. How GADA
could inhibit DR is not clear. We hypothesize that if GADA is a
factor, it would be in the progression of DR when the blood-retinal
barrier is prominently compromised, allowing GADA access to
antigen in the intra-retinal spaces, possibly modulating the
inflammatory response. Our findings suggest an increased risk of
DR for every 100 WHO units/ml increase in GADA (RR=1.12)
at the clinical onset of diabetes. However, our lack of participants
with severe NPDR and PDR and different study designs make
comparisons with these two previous studies difficult. One other
study has reported no association between GADA and DR [79].
However the methodology of the study was flawed. Cases and
controls were chosen by exposure status (24 GADA positive and
72 GADA negative subjects) instead of by the presence or absence
of DR. This would severely limit the possibility of a positive
finding.
There is a strong negative association between the DQ6
haplotype and type 1 diabetes among participants younger than 15
years of age [24]. However, the percentage of participants with the
HLA DQ6 haplotype at clinical onset increases with increasing
age and shows no association by 30–34 years of age [24]. In the
present cohort, 4.9% (12/246) of participants were positive for
HLA DQ6 which represents 14.0% (12/86) of participants not
DQ2 or 8, and it is of considerable interest whether these
Table 7. Results of relative risk regression analyses for diabetic retinopathy, secondary analyses.
Model D Model E Model F
n=204 RR 95% CI RR 95% CI RR 95% CI
DQ2/8 (vs. other
a) 0.84 0.61–1.15 0.80 0.59–1.11 0.84 0.62–1.15
DQ6 (vs. other
a) 0.49 0.21–1.13 0.50 0.22–1.15 0.48 0.21–1.12
DQ8 (vs. other
a) 1.01 0.77–1.32 1.00 0.77–1.31 1.01 0.78–1.32
DQ2 (vs. other
a) 0.66 0.44–0.99 0.69 0.46–1.03 0.65 0.43–0.99
GADA (100 WHO units/ml) 1.15 1.04–1.28 1.16 1.04–1.30
Last GADA(100 WHO units/ml) 1.12 1.00–1.24
Tertiles of loss of GADA/year
Moderate loss of GADA vs. fastest 0.99 0.73–1.35
Slowest loss of GADA vs. fastest 0.90 0.69–1.17
log(ICA+0.1) (JDF-U) 1.01 0.98–1.05 1.02 0.98–1.05 1.01 0.98–1.05
IA-2A (100 WHO units/ml) 0.92 0.84–1.00 0.92 0.84–1.00 0.91 0.84–0.99
C-peptide (nmol/l) 0.88 0.62–1.27 0.89 0.60–1.32 0.88 0.62–1.26
Tertiles of loss of C-peptide/year
Moderate loss of C-peptide vs. slowest 0.97 0.72–1.31
Fastest loss of C-peptide vs. slowest 0.99 0.75–1.30
HbA1c (%) 1.20 1.10–1.32 1.20 1.09–1.32 1.21 1.09–1.32
HTN meds (yes vs. no) 1.37 1.08–1.74 1.38 1.08–1.76 1.36 1.06–1.75
Age at Diagnosis (years) 1.00 0.98–1.02 1.00 0.98–1.02 1.00 0.98–1.03
Males (vs. Females) 1.12 0.89–1.41 1.15 0.91–1.45 1.11 0.88–1.41
Duration (years) 1.10 0.99–1.23 1.11 0.99–1.24 1.09 0.98–1.22
aOther refers to anyone without DQ2, DQ8 or DQ6.
RR: relative risk.
DQ6: DRB1*1501-DQA1*0102-B1*0602.
DQ8: DRB1*04-DQA1*0301-B1*0302.
DQ2: DRB1*0301-DQA1*0501-B1*0201.
GADA: glutamic acid decarboxylase autoantibodies.
WHO: World Health Organization.
JDF-U: Juvenile Diabetes Foundation Units.
ICA: islet cell autoantibodies.
IA-2A: insulinoma antigen 2 autoantibodies.
doi:10.1371/journal.pone.0017569.t007
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have discounted the HLA genes as a factor in the development
and progression of DR due to the number of negative studies or
the inconsistent results between studies. Previous studies were
often hampered by the use of serologic or cellular typing of the
HLA genes, had limited power, did not correct for multiple testing
or did not adequately control for duration of diabetes, blood
glucose levels and hypertension. However, at least one other study
of individuals with younger-onset type 1 diabetes reported that the
DQ6 haplotype was less common in participants with proliferative
diabetic retinopathy (PDR) [45]. They found DQ6 in 6.7% (2/30)
of participants with PDR compared to 14.0% (7/50) in
participants with non-PDR and 12.0% (6/50) in healthy controls.
In a comparison between the PDR group and the non-DR group
they reported the odds of retinopathy was 0.4 for participants with
DQ6 compared to those without. This is lower than our point
estimate of 0.7, in a cohort consisting of much less severe DR.
We were unable to demonstrate an association between the
amount of C-peptide at the onset of diabetes and the risk of DR 15
years later. We speculated that the patients with less C-peptide
would be at greater risk for DR. In the much larger retrospective
study from the DCCT, uniformly in the intensive and partially in
the conventional treatment groups, any C-peptide secretion, but
especially at higher and sustained levels of stimulated C-peptide,
was associated with reduced incidences of DR, both a single three-
step change and a repeated three-step change on the Early
Treatment of Diabetic Retinopathy Study scale at the next 6-
month visit [53].
It is not clear why our results differ from those seen in the
DCCT. The DCCT did not consider islet autoantibody status.
Another possibility is the difference in participants. To be eligible
for the DCCT, patients were required to have had insulin
dependent diabetes mellitus for one to five years and to have no
retinopathy as detected by 7-field stereoscopic fundus photogra-
phy. This is a more sensitive measure of retinopathy than we were
able to attain in our sample. Their study period was also
considerably shorter and measures of C-peptide more closely
coincided with assessment of retinopathy. It may be possible that
the absolute or nearly absolute loss of C-peptide increases the risk
of diabetic microvascular complications and that the lower
detection limit of our assay, 0.13 nmol/l, was not sensitive enough
to distinguish these participants. The C-peptide binding curve to
cell membranes of renal tubular cells, fibroblasts and endothelial
cells indicate that saturation of binding occurs at very low
concentrations [80,81] possibly indicating very little C-peptide is
needed to have the desired physiologic effect. It could also be that
no C-peptide is a factor for patients with type 1 diabetes who
develop retinopathy much earlier in the course of the disease. In
our study, we do not know when DR first presented. If that
information was available, Cox-regression could have been used to
investigate whether C-peptide had a protective effect during the
first years after the clinical onset of diabetes. Lastly, we cannot
know from the DCCT or this study if C-peptide, endogenous
insulin or both are potentially associated with DR.
Future studies will be needed to replicate these results and
ideally these studies would include time to the onset of DR and a
larger number of participants with more severe disease. Additional
studies are needed to determine to what extent GADA may
contribute to the immunofluorescence induced by serum samples
tested on retinal cells [82,83]. It is also of interest to determine if
GADA interacts with other immunologic or metabolic factors to
increase the risk of DR. Despite the number of previous studies of
HLA and DR, there remains a need for a study with an adequate
sample size to fully investigate these associations.
In conclusion, we have shown that increased levels of GADA at
the time of onset were associated with an increased risk of DR 15
years later. These results, if confirmed, could provide additional
insights into the pathogenesis of the most common microvascular
complication of diabetes and lead to better risk stratification for
both patient screenings and DR treatment trials.
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